According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

The approval in previously treated pediatric patients was based on data from the Alfa-PROTECT and PROTECT Kids studies.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

HealthDay News — Drug overdose deaths decreased by 26.9% from 2023 to 2024, according to provisional data released today from the National Center for Health Statistics.

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Brekiya consists of dihydroergotamine mesylate, an ergotamine derivative, in a single-dose autoinjector for subcutaneous administration.

The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A microsphere) injectable suspension for use in pediatric patients with suboptimal echocardiograms to opacify the ...

The Food and Drug Administration (FDA) has approved Welireg ™ (belzutifan) for the treatment of adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic ...

Order expected to affect specific medications covered under Medicare that are administered in a health care setting.